Loading stock data…
PTCT
$65.15+0.09 (+0.14%)
Market ClosedLast close May 1
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PTC Therapeutics, Inc. in the Healthcare sector is trading at $65.15. The stock is currently 26% below its 52-week high of $87.50, remaining 2.0% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why PTCT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$65.15
Potential Downside
624.2%
Whystock Fair Value$-341.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$88.07+35.2%
Range$61.00 – $124.00
Fundamentals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.87B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.26
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-306.45%
Volume
Today's trading volume
1.05M
Recent News
PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone
Earlier this week, PTC Therapeutics reported positive 24‑month interim data from the PIVOT-HD extension study, showing dose-dependent slowing of Huntington’s disease progression with votoplam and a favorable long-term safety and biomarker profile versus an external natural history cohort. At the same time, Novartis’ launch of the large Phase 3 INVEST-HD trial, which triggered a US$50,000,000 milestone payment, underscores growing industry commitment to advancing votoplam toward potential...
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals
PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington’s disease, highlighting what the company described as continued favorable safety and signals of dose-dependent slowing of diseas
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
KROS Rinvatercept: What to Know Before DMD Phase II Starts
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.